Scaffold hopping from synthetic RXR modulators by virtual screening and de novo design.

The lack of potent subtype-selective modulators of retinoid X receptors (RXRs) has hindered their full exploitation as promising drug targets. Using computational similarity searching, target prediction and automated de novo design, we identified novel RXR ligands exhibiting innovative molecular frameworks, pronounced receptor-subtype preference and suitable properties for hit-to-lead expansion.

[1]  Anton Simeonov,et al.  Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. , 2012, Chemistry & biology.

[2]  P. Chambon,et al.  Retinoid X receptor gamma signaling accelerates CNS remyelination , 2011, Nature Neuroscience.

[3]  H. Kakuta,et al.  Retinoid X receptor ligands: a patent review (2007 – 2013) , 2014, Expert opinion on therapeutic patents.

[4]  Ewgenij Proschak,et al.  Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.

[5]  A. D. de Lera,et al.  Natural and Structure-based RXR Ligand Scaffolds and Their Functions. , 2017, Current Topics in Medicinal Chemistry.

[6]  G. Thatcher,et al.  Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. , 2017, Current topics in medicinal chemistry.

[7]  Gerd Geisslinger,et al.  A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.

[8]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[9]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[10]  Markus Hartenfeller,et al.  DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..

[11]  Ewgenij Proschak,et al.  Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.

[12]  Gregor Eichele,et al.  International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.

[13]  M. Berciano,et al.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases , 2016, Journal of Neurology.

[14]  Petra Schneider,et al.  Scaffold Hopping by “Fuzzy” Pharmacophores and its Application to RNA Targets , 2007, Chembiochem : a European journal of chemical biology.

[15]  G. Schneider,et al.  Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts , 2006, ChemMedChem.

[16]  Gisbert Schneider,et al.  Flashback Forward: Reaction-Driven De Novo Design of Bioactive Compounds , 2013 .

[17]  Petra Schneider,et al.  Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules , 2013, Molecular informatics.

[18]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[19]  A. D. de Lera,et al.  An Endogenous Mammalian Retinoid X Receptor Ligand, At Last! , 2016, ChemMedChem.

[20]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[21]  Petra Schneider,et al.  Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.

[22]  Igor V. Tetko,et al.  Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..

[23]  L Zhang,et al.  Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. , 1994, Journal of medicinal chemistry.